Clinical Research
Title: A Prospective, Nonrandomized, Open Label, Single Arm, Multicenter, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Human Normal Immunoglobulin for Intravenous Administration in Adult Patients with Chronic Primary Immune Thrombocytopenia.
Title: A Randomized, Double-Blind, Multicenter, Parallel Group, Clinical Trial to Compare Efficacy, Safety and Immunogenicity of Intas Pertuzumab with Perjeta® (In combination with Trastuzumab and Docetaxel) in Patients with HER2-Positive Metastatic Breast Cancer.
Title: Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevac-izumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevaciz-umab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).
A Prospective, Randomized, Open-label, Parallel Group, Active-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy, Safety, Immunogenicity and Pharmacokinetics of Proposed Trastuzumab Emtansine Biosimilar Compared with Kadcyla® in HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Treatment with Trastuzumab and a Taxane
A randomized, double-blind, multi-center, active-control, parallel group study to compare efficacy, safety, immunogenicity and pharmacokinetics of Lupin’s Nivolumab (LUBT022) with Innovator’s Nivolumab in patients with locally advanced or metastatic non-small cell lung cancer.
